These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669 [TBL] [Abstract][Full Text] [Related]
44. Brain imaging in Alzheimer disease. Johnson KA; Fox NC; Sperling RA; Klunk WE Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a006213. PubMed ID: 22474610 [TBL] [Abstract][Full Text] [Related]
45. Prevalence and prognosis of prodromal Alzheimer's disease as assessed by magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography in a community: reanalysis from the Osaki-Tajiri Project. Meguro K; Akanuma K; Meguro M; Yamaguchi S; Ishii H; Tashiro M Psychogeriatrics; 2016 Mar; 16(2):116-20. PubMed ID: 26114837 [TBL] [Abstract][Full Text] [Related]
46. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW; Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191 [TBL] [Abstract][Full Text] [Related]
47. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study. Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253 [TBL] [Abstract][Full Text] [Related]
48. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid. Schipke CG; Koglin N; Bullich S; Joachim LK; Haas B; Seibyl J; Barthel H; Sabri O; Peters O Psychiatry Res Neuroimaging; 2017 Jul; 265():98-101. PubMed ID: 28024844 [TBL] [Abstract][Full Text] [Related]
49. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733 [TBL] [Abstract][Full Text] [Related]
50. Alzheimer's Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject. Tiepolt S; Patt M; Hoffmann KT; Schroeter ML; Sabri O; Barthel H J Alzheimers Dis; 2015; 47(3):539-43. PubMed ID: 26401690 [TBL] [Abstract][Full Text] [Related]
52. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653 [TBL] [Abstract][Full Text] [Related]
53. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Blennow K; Zetterberg H Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576 [TBL] [Abstract][Full Text] [Related]
54. Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. Benvenutto A; Giusiano B; Koric L; Gueriot C; Didic M; Felician O; Guye M; Guedj E; Ceccaldi M J Alzheimers Dis; 2018; 65(4):1147-1157. PubMed ID: 30124446 [TBL] [Abstract][Full Text] [Related]
55. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942 [TBL] [Abstract][Full Text] [Related]
56. Why Is Amyloid-β PET Requested After Performing CSF Biomarkers? Reimand J; Groot C; Teunissen CE; Windhorst AD; Boellaard R; Barkhof F; Nazarenko S; van der Flier WM; van Berckel BNM; Scheltens P; Ossenkoppele R; Bouwman F J Alzheimers Dis; 2020; 73(2):559-569. PubMed ID: 31796674 [TBL] [Abstract][Full Text] [Related]
57. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O; Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982 [TBL] [Abstract][Full Text] [Related]